BFA
NVCR icon

Beaumont Financial Advisors’s NovoCure NVCR Stock Holding History

Beaumont Financial Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$232K – 368
2021
Q3 		$232K Hold
2,000
– – 0.02% 315
2021
Q2 		$444K Buy
+2,000
New +$389K 0.03% 226

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Beaumont Financial Advisors's NVCR Position: Q4 2021 in Review

Beaumont Financial Advisors sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 2,000 shares — an estimated $232K sold.

Beaumont Financial Advisors first reported a position in NVCR in Q2 2021 and held it in 2 quarters. The position peaked at $444K in Q2 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Beaumont Financial Advisors reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Beaumont Financial Advisors sold 2,000 NovoCure shares in Q4 2021, an estimated $232K.
  • Beaumont Financial Advisors first reported a position in NovoCure in Q2 2021 and held it in 2 quarters.
  • Beaumont Financial Advisors's NovoCure position peaked at $444K in Q2 2021.
  • 311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Beaumont Financial Advisors's 13F filing for Q4 2021, filed 7 Feb 2022.